Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions

Healthy

Interventions

DRUG

INX-08189 50 mg

Study Day 0: Single 50 mg dose of INX-08189 in the morning

DRUG

240 mg verapamil HCL ER

Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning

DRUG

50 mg dose of INX-08189 and 240 mg verapamil HCL ER

Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning

Trial Locations (1)

Prism Research, LLC, Saint Paul